
---
nice.evidencecategory: 
---

### Evidence Statement CG66HES4
In the 2005 cost-utility analysis the discounted cost (6% discount rate) of an intensive blood
glucose control policy with insulin or sulphonylureas was on average 884 more per patient and
the discounted benefits gained were 0.15 quality of life-adjusted year (QALY), a cost per QALY
gained of 6,028.33

